• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Flucytosine plus fluconazole is noninferior to amphotericin B in treating cryptococcal meningitis

byIyas DaghlasandDayton McMillan
March 20, 2018
in Chronic Disease, Emergency, Infectious Disease, Neurology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Treatment of cryptococcal meningitis with two weeks of flucytosine and fluconazole was noninferior to two weeks of amphotericin B.

2. Addition of flucytosine to amphotericin B was superior to amphotericin B plus fluconazole.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Cryptococcal meningitis accounts for a significant burden of morbidity and mortality in HIV-infected adults. Although current treatments for this opportunistic infection are effective, there is a need for efficacious treatment regimens that are more widely available. The gold standard induction therapy, two weeks of amphotericin B and flucytosine, is not available at most African clinical centers. This noninferiority clinical trial sought to assess the efficacy of combined oral flucytosine and fluconazole compared to amphotericin B among HIV-seropositive adults with cryptococcal meningitis, and determine what is an optimal drug to add to amphotericin B treatment regimens. Mortality at two weeks after treatment initiation was the primary outcome. The combination of flucytosine and fluconazole for two weeks was noninferior to two weeks of amphotericin B therapy. Addition of flucytosine to amphotericin B resulted in superior mortality outcomes relative to fluconazole add-on therapy. The most effective regimen tested was one week of amphotericin B plus flucytosine. Adverse events, including anemia and kidney injury, were most common with two weeks of amphotericin B. These results support efforts to increase accessibility of flucytosine in regions with a high burden of HIV infection.

A major strength of this study is its multicenter, randomized design. Results were consistent across both multivariable adjusted and sensitivity analyses. The use of daily intravenous normal saline and potassium and magnesium supplementation for those treated with amphotericin B might preclude generalizability of the efficacy and safety of amphotericin B treatment regimens.

Click to read the study, published in NEJM

Relevant Reading: Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

RELATED REPORTS

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

High-dose Hepatitis B revaccination schedule improves serological response among patients with Human Immunodeficiency Virus

In-Depth [randomized controlled trial]: This was a phase three, open-label randomized controlled trial that enrolled patients from nine African centers. Inclusion criteria included HIV-seropositive status, a diagnosis of cryptococcal meningitis supported by either India ink staining or Cryptococcal antigen assay, and lack of multiple prior exposures to study drugs. The treatment arms included: i) two weeks of oral fluconazole and flucytosine, ii) one week of amphotericin B with either flucytosine or fluconazole, and iii) two weeks of amphotericin B with either flucytosine or fluconazole. The primary outcome was mortality at two weeks. Secondary outcomes included mortality at four and ten weeks, as well as rate of CSF fungal clearance.

The absolute rates of mortality at two weeks in the treatment arms were similar, with the 95% confidence intervals for difference in rates of mortality overlapping zero and meeting criteria for noninferiority (rate of mortality at two weeks: oral-regimen 18.2% (41/225); 1-week amphotericin B 21.9% (49/224); 2-week amphotericin B 21.4% (49/229)). When added to amphotericin B, flucytosine was associated with a lower risk of death relative to fluconazole (hazard ratio for death at 10 weeks [HR], 0.62; 95% confidence interval [CI], 0.45 to 0.84; p = 0.002). The rate of clearance of infection in cerebrospinal fluid was faster in the amphotericin B groups compared to the oral-regimen group, and was maximized with flucytosine add-on therapy. Grade 4 anemia developed in 8.8% of patients in the 2-week amphotericin B group compared to 0.9% in the oral-regimen group. Similar trends were seen in rates of kidney injury.

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cryptococcushuman immunodeficiency virus (HIV)
Previous Post

Early intrauterine Zika infection linked to birth defects among infants in the US French Territories

Next Post

Extremely preterm children more likely to develop motor impairment

RelatedReports

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up
Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

May 18, 2022
Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Chronic Disease

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

March 29, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

High-dose Hepatitis B revaccination schedule improves serological response among patients with Human Immunodeficiency Virus

August 24, 2021
Government-funded initiatives provide important supports to low-income HIV patients
Chronic Disease

Targeted screening not superior to nontargeted screening for human immunodeficiency virus in the emergency department

July 29, 2021
Next Post
Rapid genetic testing useful for diagnosis of critically ill children

Extremely preterm children more likely to develop motor impairment

Parental hopes for critically ill children are dynamic

Parental hopes for critically ill children are dynamic

USPSTF: Behavioral interventions do not reduce sunburn or skin cancer outcomes in adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prior syncope presentation not associated with increased risk of motor vehicle collision
  • Baricitinib reduces mortality risk in patients hospitalized with COVID-19
  • Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.